Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GOT1 | P17174 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL27650673 | 0.89 | SMN1; SMN2 (0.44) | TSHRCYP19A1NPC1RAB9AKMT2A | |
| SCHEMBL7069713 | 0.76 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL31738482 | 0.76 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL29481851 | 0.75 | CYP19A1 (0.53) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL871138 | 0.75 | CYP19A1 (0.53) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6061889 | 0.74 | CYP19A1 (0.52) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL9807642 | 0.73 | CYP19A1 (0.54) | CYP19A1NPC1RAB9AGAAKMT2A | |
| SCHEMBL7664932 | 0.72 | TSHR (0.51) | TSHRNPC1RAB9AALDH1A1HRH3 | |
| SCHEMBL8372463 | 0.72 | LMNA (0.47) | CYP19A1NPC1RAB9AGAAKMT2A | |
| SCHEMBL19952861 | 0.72 | LMNA (0.52) | CYP19A1NPC1RAB9AGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286795-A1 | USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | LITTLEWOOD-EVANS AMANDA J | 2009-11-19 | — | — | US | claimed |
| US-20090239872-A1 | TREATMENT OF MESOTHELIOMA | HOHNEKER JOHN ARTHUR | 2009-09-24 | — | — | US | claimed |
| US-20090233939-A1 | TREATMENT OF AMM | GILES FRANK | 2009-09-17 | — | — | US | claimed |
| US-20090196871-A1 | USE OF 4-PYRIDYLMETHYLPHTHALAZINES FOR CANCER TREATMENT | DUGAN MARGARET HAN | 2009-08-06 | — | — | US | claimed |
| CN-101460171-A | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | claimed |
| EP-2029144-A1 | USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2009-03-04 | — | — | EP | claimed |
| EP-1712234-B1 | Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment | NOVARTIS AG (CH) | 2009-01-28 | — | — | EP | claimed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | claimed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | claimed |
| WO-2007140924-A1 | USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | claimed |
| EP-1545534-A1 | USE OF 4-PYRIDYLMETHYL-PHTHALAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | Novartis AG (CH) | 2005-06-29 | — | — | EP | claimed |
| JP-2005502690-A | — | — | 2005-01-27 | — | — | JP | claimed |
| US-20040258770-A1 | Use of 4-pyridylmethylphthalazines for cancer treatment | DUGAN MARGARET HAN (US) | 2004-12-23 | — | — | US | claimed |
| CN-1553803-A | Use of 4-pyridylmethylphthalazines for the treatment of cancer | ��˹��ŵ�� | 2004-12-08 | — | — | CN | claimed |
| WO-2004056367-A1 | TREATMENT OF VON HIPPEL LINDAU DISEASE | DANA-FARBER CANCER INSTITUTE INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1427420-A1 | USE OF 4-PYRIDYLMETHYLPHTHALAZINES FOR CANCER TREATMENT | Novartis AG (CH) | 2004-06-16 | — | — | EP | claimed |
| WO-2004043459-A1 | TREATMENT OF MESOTHELIOMA | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | claimed |
| WO-2004033042-A1 | TREATMENT OF AMM | NOVARTIS AG (CH) | 2004-04-22 | — | — | WO | claimed |
| WO-2004028542-A1 | USE OF 4-PYRIDYLMETHYL-PHTHALAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | claimed |
| WO-2003022282-A1 | USE OF 4-PYRIDYLMETHYLPHTHALAZINES FOR CANCER TREATMENT | NOVARTIS AG (CH) | 2003-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | TSHR 952/4885CYP19A1 634/4885NPC1 1208/4885 |
| US-20090239872-A1 | TREATMENT OF MESOTHELIOMA | CD47, MB, MGMT | TSHR 3218/4885CYP19A1 4290/4885NPC1 4839/4885 |
| US-20090233939-A1 | TREATMENT OF AMM | MYADM, NPM1, SLC11A2 | TSHR 2644/4885CYP19A1 1317/4885NPC1 4458/4885 |
| US-20090286795-A1 | USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | LDHA, LDHB, KDR | TSHR 1994/4885CYP19A1 3566/4885NPC1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.